Increased Earnings Estimates Seen for Osiris (OSIR): Can It Move Higher? - Tale of the Tape

by Zacks, Benzinga Contributor
May 16, 2014 9:31 AM | 2 min read | Make a Comment
Loading...
Loading...
Osiris Therapeutics, Inc. OSIR is a company in the biotechnology sector that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on OSIR's earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Osiris could be a solid choice for investors.

Current Quarter Estimates for OSIR

In the past 30 days, 1 estimate have gone higher for Osiris while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates substantially improving from a loss of 12 cents a share 30 days ago, to earnings of 30 cents today.

Current Year Estimates for OSIR

Meanwhile, Osiris' current year figures are also looking quite promising, with 2 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, substantially improving a loss of 25 cents per share 30 days ago to earnings of 9 cents per share today.

Bottom Line

The stock has also started to move higher lately, adding 27.89% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report

OSIRIS THERAPTC OSIR: Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!